Related Experiment Video
Updated: Oct 12, 2025
07:32
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
7.9K
Screening a Molecular Fragment Library to Modulate the PED/PEA15-Phospholipase D1 Interaction in Cellular Lysate
Biancamaria Farina1, Luciano Pirone1, Gianluca D'Abrosca2
1Istituto di Biostrutture e Bioimmagini, CNR, via Mezzocannone 16, 80134 Napoli, Italy.
ACS Chemical Biology
|November 26, 2021
Summary
Researchers identified small molecules that inhibit the interaction between PED and PLD1, a key factor in type II diabetes. This discovery offers a new therapeutic strategy to improve insulin sensitivity and glucose tolerance.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Overexpression of PED/PEA15 (phosphoprotein enriched in diabetes/phosphoprotein enriched in the astrocytes 15) is linked to type II diabetes.
- PED inhibits insulin-stimulated glucose transport by interacting with phospholipase D1 (PLD1).
- Inhibiting the PED/PLD1 interaction can restore glucose transport, highlighting PED as a drug target.
Purpose of the Study:
- To identify and select small molecule ligands that target PED.
- To characterize the PED/PLD1 interaction in a cellular lysate environment.
- To evaluate the potential of identified ligands as therapeutic agents for type II diabetes.
Main Methods:
- NMR screening of a small molecule library to identify PED ligands.
- NMR characterization of the PED/PLD1 interaction in cell lysates.
- Modulation of PED/PLD1 interaction using the selected ligand BPH03.
Main Results:
- Identification and selection of PED ligands from a small molecule library.
- Detailed structural information on the PED/PLD1 interaction in a cellular lysate.
- Demonstration that BPH03 modulates the PED/PLD1 interaction.
Conclusions:
- PED is a viable pharmacological target for type II diabetes treatment.
- BPH03 serves as a valuable scaffold for developing novel compounds to improve insulin sensitivity.
- The findings provide a foundation for new therapeutic strategies targeting glucose metabolism in type II diabetes.
